secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-06-22T11:22:36+00:00
Accession:  0001140361-26-025841
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee licenses exclusive worldwide rights to IL-31R antibodies from Paragon with up to $23.25M in milestones
--------------------------------------------------------------------------------

- Exclusive worldwide license from Paragon for monospecific antibodies directed to interleukin-31 receptor (IL-31R).
- Milestone payments up to $23.25 million, including $5.25 million upon first Phase I dosing.
- Low-single digit royalties on net sales of products under the license.
- Paragon retains non-exclusive rights for multispecific antibodies; Apogee has right of first negotiation.
- Optional CMC activities fees range from $1.3 million to $2.0 million under the discovery agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000114036126025841/0001140361-26-025841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000114036126025841/ef20076542_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-025841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer